Cisplatin administration to gynecologic cancer patients: Long term effects on hearing

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Cancer

• Publication date

  1996-10-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/(SICI)1097-0142(19961015)78:8<1798::AID-CNCR22>3.0.CO;2-SPMID 8859195
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The long-term retention of platinum in human tissues following the administration of cisplatin or carboplatin for cancer chemotherapy.

  1992cited by this paper
• Treatment of advanced ovarian cancer: 10 years of experience.

  1992cited by this paper
• Long-term effects of chemotherapy in patients with testicular cancer.

  1992cited by this paper
• Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer.

  1990cited by this paper
• Long-term toxicity of chemotherapy for testicular cancer--the cost of cure.

  1990cited by this paper
• High‐Dose cisplatin treatment: Hearing loss and plasma concentrations

  1990cited by this paper
• Second cancers and other late side effects of cancer treatment.A review

  1990cited by this paper
• The incidence of aminoglycoside antibiotic-induced hearing loss.

  1990cited by this paper
• The ototoxic effect of cisplatin on guinea pigs in relation to dosage.

  1989cited by this paper
• Ototoxicity of cisplatin in gynaecological cancer patients.

  1988cited by this paper
• Cisplatin ototoxicity in gynecologic cancer patients. A preliminary report

  1985cited by this paper
• Ototoxicity of cis-diamminedichloroplatinum (II): influence of dose, schedule and mode of administration.

  1983cited by this paper
• Audiometric monitoring of cis-platinum ototoxicity.

  1983cited by this paper
• Comparison of manual and computer-controlled audiometry using identical procedures.

  1983cited by this paper
• Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration.

  1982cited by this paper
• Auditory toxicity effects of long‐term cis‐dichlorodiammineplatinum II therapy in genitourinary cancer patients

  1981cited by this paper
• Cis‐dichlorodiammine platinum and adriamycin therapy for advanced gynecological and genitourinary neoplasms

  1980cited by this paper
• Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.

  1976cited by this paper
• Presbycusis Values in Relation to Noise Induced Hearing Loss

  1967cited by this paper

• Protection from cisplatin-induced hearing loss with lentiviral vector-mediated ectopic expression of the anti-apoptotic protein BCL-XL

  2024cites this paper
• FTO protects human granulosa cells from chemotherapy-induced cytotoxicity

  2022cites this paper
• Overexpression of FTO Protects Human Granulosa Cells From Cisplatin-Induced Injury

  2021cites this paper
• Investigation of TAp63 gene expression and follicle count using melatonin in cisplatin-induced ovarian toxicity

  2020cites this paper
• Synergistic effect of melatonin and ghrelin in preventing cisplatin‐induced ovarian damage via regulation of FOXO3a phosphorylation and binding to the p27Kip1 promoter in primordial follicles

  2017cites this paper
• EFFECT OF CHRONOMODULATED ARTESUNATE ON RENAL AND HAEMATOLOGICAL TOXICITY IN CISPLATIN-TREATED WISTAR RATS

  2017cites this paper
• The chemopreventive effect of Ginkgo biloba extract 761 against cisplatin ototoxicity: a pilot study.

  2015cites this paper
• Pharmacokinetics and inner ear transport of cisplatin

  2015cites this paper
• Associations between dietary quality, noise, and hearing: Data from the National Health and Nutrition Examination Survey, 1999–2002

  2014cites this paper
• A density functional reactivity theory (DFRT) based approach to understand the interaction of cisplatin analogues with protecting agents

  2014cites this paper
• Magnesium Salts in a Cancer Patient: Pathobiology and Protective Functions

  2013cites this paper
• Cochlear pharmacokinetics of cisplatin: An in vivo study in the guinea pig

  2013cites this paper
• Neurotoxicity Caused by the Treatment with Platinum Analogues

  2011cites this paper
• Prevention of cisplatin-induced hearing loss by administration of a thiosulfate-containing gel to the middle ear in a guinea pig model

  2011cites this paper
• Local pharmacological treatment of inner ear disorders

  2011cites this paper
• Vestibular and Auditory Ototoxicity

  2010cites this paper
• Distortion-product otoacoustic emissions and auditory brainstem responses sensitivity assessment in cisplatin-induced ototoxicity in rats

  2009cites this paper
• A relevant historical perspective on the current toxicity of IP chemotherapy: implications for the future.

  2007cites this paper
• High‐Dose Cisplatin With Amifostine: Ototoxicity and Pharmacokinetics

  2004cites this paper
• Toxicity of platinum compounds

  2003cites this paper
• Toxicities of the platinum antineoplastic agents

  2003cites this paper
• Distortion product otoacoustic emissions test is useful in children undergoing cisplatin treatment.

  2003cites this paper
• Resilience, reflection, and residual stress in ovarian cancer survivorship: A gynecologic oncology group study

  2002cites this paper
• Reproductive Health LiteratureWatch

  1997cites this paper